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TERT promoter mutation during development of hepatoblastoma
to hepatocellular carcinoma
mutationswere signiﬁcantly associatedwith histological (pseudo-
glandular formation, cytological atypias, and unpaired arteries)
and immunohistochemical (positive staining for GPC3 and
HSP70) features of malignancy [5].
Therefore, Eichenmüller et al. should further evaluate their
data by examining paediatric HCC patient samples for the afore-
mentioned histological and immunohistochemical features.
Alternatively, a larger case-control study that incorporates the
above-mentioned points is required.
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JOURNAL OF HEPATOLOGYTo the Editor:
We read with great interest the article by Eichenmüller et al. [1],
who used whole-exome sequencing to describe the genomic
landscape of hepatoblastoma (HB) cells and their progenies with
hepatocellular carcinoma (HCC)-like features. They concluded
that mutation of CTNNB1 and activation of the NFE2L2-KEAP1
pathway are important features in HB-development and further
deﬁne loss of genomic stability and TERT promoter mutations
as prominent characteristics of aggressive HB with HCC features.
Although we appreciate these impressive ﬁndings, there are
some important considerations that need to be stressed.
First, HB and HCC share a common CTNNB1 mutation, which
leads to activation ofWnt signalling and the genesis of liver cancer
in both adults and children. The oncogene TERT has been shown to
regulate CTNNB1 expression, while conversely b-catenin can bind
to the TERT promoter to positively inﬂuence TERT expression [2,3].
TERT promoter mutations are commonly involved in the last step
of malignant transformation in association with CTNNB1 muta-
tions in HCC [4]. Eichenmüller et al. showed that the expression
of TERT was upregulated in both HB and transitional liver cell
tumours (TLCT). However, TERT promoter mutations were identi-
ﬁed in two thirds of TLCTs analysed but not in any instances of HB.
They concluded that the TERT promoter mutation is a selective
phenomenon for advanced HB with HCC-like features. However,
only three patients were included as TLCT controls, and the
cause(s) of their disease were not speciﬁed. Moreover, one of
the TLCT controls did not possess mutations of the TERT promoter.
This limited incidence of TLCT may inﬂuence the conclusion that
TLCT is a genetically derailed progeny of HB. Analysis of TERT pro-
moter mutations in paediatric HCC may assist in making such a
conclusion more convincing.
Second, it has been recently reported that the TERT promoter
mutation is an early event in liver carcinogenesis of cirrhosis,
based upon analysis of the sequence of lesions from cirrhosis to
low-grade dysplastic nodules (LGDN), high-grade dysplastic nod-
ules (HGDN), early HCC (eHCC) and small and progressed HCC.
TERT promoter mutations occurred in a small proportion of dys-
plastic nodules (6% of LGDN and 19% of HGDN), and the prevalence
increased with the degree of dysplasia. The prevalence of TERT
promoter mutations was dramatically increased in eHCC (61%),
suggesting a molecular shift had occurred following development
of eHCC [5]. These ﬁndings suggest that TERT promoter mutations
might be an important mechanism to drive malignant liver cells
towards a more aggressive eHCC-like phenotype. TERT promoter
mutations may therefore be a selective phenomenon of advanced
HB with eHCC-like features. Furthermore, TERT promoter
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